Actelion shares fall on report it rejects J&J offer
- Wall Street flat as telecom gains fail to counter oil drop
- Equinix (EQIX) Announces $3.6B Acquisition of Data Center Portfolio from Verzion (VZ)
- Trump Wants to Cancel New Air Force One Order with Boeing (BA)
- Roper Industries (ROP) to acquire Deltek in $2.8B Deal
A general view shows Swiss biotech group Actelion Headquarters in Allschwil near Basel February 17, 2015. REUTERS/Arnd Wiegmann
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
ZURICH (Reuters) - Shares in Swiss biotech company Actelion fell more than 6 percent after news outlet streetinsider.com reported on Wednesday the company had rejected a full takeover offer by U.S. healthcare group Johnson & Johnson and may sell a unit.
Actelion declined to comment on the report, which cited an unidentified source, and referred to a statement the company had published on Friday. The companies had confirmed last week they were in talks about a possible transaction.
(Reporting by Paul Arnold, Editing by Michael Shields)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Norway's Schibsted to hire more staff to stave off Facebook in classified ads
- Boeing expects business jet sales to recover in next two years
- JPMorgan CEO says bank may look to pay special dividend
Create E-mail Alert Related CategoriesReuters
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!